A MORE ACCURATE ASSESSMENT ON SKIN CANCER IS THE WAY MEDX PLANS TO SAVE THE PLANET - INVESTORINTEL

A more accurate assessment on
skin cancer is the way MedX
plans to save the planet
No one should ever die of skin cancer.
Wow – doesn’t that just wake you up a little bit? The
deadliest cancers include lung and bronchial cancer, colon and
rectal cancer, breast cancer, pancreatic cancer, prostate
cancer, leukemia, Non-Hodgkin lymphoma, liver cancer, melanoma
and ovarian cancer. According to the American Cancer Society
in their July 2018 report, in the period from 2008 – 2014,
overall cancer incidence rates decreased by 2.2% in men and
remained stable in women. From 1999 – 2014, overall cancer
deaths decreased by 1.8% per year among men and 1.4% per year
among women.

Unfortunately, melanoma (skin cancer) still ranks in the “top
ten” among both men and women – not a ranking that we really
need to be ecstatic about.

Enter MedX Health Corp. (TSXV: MDX). Originally founded in
1999 with a focus on laser and phototherapy products, the
company still maintains this highly reputable product line in
a very competitive global marketplace. MedX first acquired
their other product technology (SIAscope) in 2011 and through
improvements, has positioned MedX as a leading medical device
and software company.

Focused on the early detection of skin cancer, MedX’s SIAscope
is a handheld Class IIA medical device. First, the SIAscope
takes 5 images, including 4 spectrophotometric images 2 mm
below the skin’s surface showing the disorganization of a
suspicious mole or lesion. This allows dermatologists to make
a more accurate assessment based on the underlying physiology

of the skin. MedX is the only technology in the world that can
present this additional critical imaging, taking remote
medicine to a new and improved level for provision of timely,
accurate diagnoses.

Second, SIAscopy on DermSecure™ captures the dermatological
images from the SIAscope and forwards them for assessment by a
dermatologist. SIAscopy is a fully integrated service that
combines innovative, peer-reviewed technology with a secure,
cloud-based patient management system. It’s the only tool that
offers perfect image capture technology with clinical,
dermascopic and spectrophotometric views of moles and other
skin conditions. Designed by dermatologists and physicians,
SIAscopy is being used in over 200 pharmacies in 3 countries
with regulatory approvals in 35 countries including USA,
Canada, Australia, Brazil and the EU.

Finally, the results are communicated back to healthcare
providers and patients. In 72 hours or less – timely
turnaround indeed! MedX stores patient’s information for 10
years, which means a patient can retrieve their patient file
and take another scan of the same mole or lesion years later
and compare it to previous images to see if there has been any
change. MedX is the only company in the world that has made
this commitment to the patient and their providers. Privacy
policies comply with all regulations in jurisdictions in which
the company operates including PIPEDA, HIPAA and GDPR. In
addition, they deploy the latest in security measures, engage
in rigorous third-party threat testing and real-time
monitoring.

Wow – who knew that it could be that easy? It really isn’t, as
the team at MedX has put decades of knowledge, expertise and
technology into development of a world-leading suite of tools.
In addition to a highly experienced leadership team and Board
of Directors, the company has assembled a Medical Advisory
Board with experts from Canada, the UK and the US, all
specialists in their fields who bring a wealth of knowledge

and expertise to MedX.

The company has a very small market capitalization compared to
similar companies in the US – only about C$20 million. The
technology is leading edge, although the market also cares
about revenue which has been negatively impacted by the
ongoing coronavirus pandemic.

The company has the longevity and the expertise in a
competitive marketplace. Management is embarking on a program
to raise global awareness to improve future revenues and cash
flow and they have raised new equity capital of just over
C$3.0 million in 2020, significantly reducing negative working
capital. Apparently there will never be less cancer in the
world and here is a technology company that can at the very
least help in the goal that “cancer can be beaten”.

Predictmedix is starting to
commercialize as AI health
screening & monitoring takes
off
Health screening is big business these days. The latest way is
using Artificial Intelligence (AI) to mass screen and/or
monitor for impairment and various disease states, including
COVID-19.

One company is now starting to commercialize their technology,
winning contracts and forming distribution partners all around
the globe. That company is Predictmedix Inc. (CSE: PMED |
OTCQB: PMEDF).

The global market size for AI        in healthcare in 2017 was
US$1.4b and is forecast to rise     to reach US$28b by 2025, for
an approximate 20 fold increase      in just 8 years. Healthcare
screening and monitoring using AI   can play a key role.

The global market for artificial intelligence           (AI)   in
healthcare is forecast to take off

Source

Predictmedix has developed leading disruptive AI technology in
impairment detection and healthcare screenings. Their AI
powered products use facial, thermal, video and audio
recognition technologies to determine when individuals are
suffering from infectious disease, are drug or alcohol
impaired, or have a mental illness. The Predictmedix screening
devices are backed up by a remote patient monitoring platform.

Source

Predictmedix’s latest achievements to commercialize their
screening AI technology

     October 1, 2020 – Partnered with Versus Systems to
     develop tools for clinical trials, in particular on-site
     monitoring to ensure human subject protection, data
     integrity, and quality. The news release states: “This
     will allow Predictmedix to enter a new industry vertical
     of clinical trials which is a $40 billion market
     opportunity as estimated by Fortune Business Insights.”
     September 3, 2020 – Predictmedix Inc. and Juiceworks
     Exhibits provide safe entry solutions to facility
     managers at IFMA World Workplace in Texas.
     August 17, 2020 – Predictmedix Inc. and Juiceworks
     Exhibits announce COVID-19 technology deployments in
     North America.
     August 12, 2020 – Deployment of Impairment Screening
     along with COVID-19 symptom screening technology at
     Indian Oil Corporation.
     July 7, 2020 – Sales/distributor 1 year contract with
     Taurus Medical in the United Kingdom. Taurus Medical

manufacture and market over 1,500 products for the
     diagnosis, treatment and monitoring of respiratory
     conditions. They are a supplier for the UK National
     Health Service. Taurus is offering Predictmedix COVID-19
     mass screening entry modules to the healthcare, retail,
     and the entertainment sector in the UK.
     June 26, 2020 – Teamed up with Tech Mahindra who will
     resell Predictmedix to their global client base. Tech
     Mahindra is a $4.9 billion dollar company owned by
     Mahindra Group. Tech Mahindra is operational across 90
     countries, helping 973 global customers including
     Fortune 500 companies.

Regarding the Indian Oil Corporation contract Predictmedix
state:

“The deployment of our COVID-19 screening and impairment
technology at IOCL which is a fortune 500 company marks our
entry into the Oil & Gas sector which is one of the largest
industrial sectors and it further highlights the market need
for the suite of technologies developed by Predictmedix.”

Now that’s a very busy past 5 months. The model of using well
known brands (Juiceworks Exhibits, Taurus Medical, Tech
Mahindra) with large distribution networks should make for a
faster and more successful commercialization. Product
deployment at large corporations such as Indian Oil
Corporation show solid early demand for the Predictmedix
product.

Predictmedix operates under a SaaS model. Clients pay a
monthly fee based on tiered volume of screenings or by number
of device feeds. Both pricing options provide Predictmedix
with recurring monthly revenue and multi-year contracts.

Right now as COVID-19 cases approach 40 million (and 1.2
million deaths) it certainly looks like there is a massive
potential market for Predictmedix’s COVID-19 Safe Entry

Solutions. This could be the product that rapidly launches
Predictmedix into the AI health screening market. You can read
more on that here.

Predictmedix current market cap is C$58m. The Company looks to
have plenty of growth opportunities ahead as it strives to
capture a share of the forecast US$28b AI healthcare market by
2025.

Further learning

     Predictmedix’s Dr. Rahul Kushwah on using AI to solve
     real world problems

Predictiv AI debuts real-
world problem solver, a fever
detection    system    called
ThermalPass

“If you can predict the future, you can
profit from it…”
All you good capitalists out there should be salivating at
that comment. It’s from the homepage of Predictiv AI Inc.
(TSXV: PAI | OTC: INOTF | FRANKFURT: 71TA) and as you may have
surmised, their business is the business of artificial
intelligence (AI). Predictiv AI “is a technology company which
helps businesses and organizations make smarter decisions
using advanced artificial intelligence, deep machine learning
and data science techniques.”

The global AI market is expected to grow in leaps and bounds –
by as much as 40-50% per year – in the next decade or so. This
makes it a market that could be in the trillions of dollars –
there is money to be made and Predictiv AI is positioned to be
a part of that. End users of AI include almost anything – the
automotive industry (self-driving vehicles especially), the
healthcare    industry,    banking,    finance,   insurance,
manufacturing and agriculture to mention just a few that are
important in our daily lives.

Predictiv AI has two subsidiaries – AI Labs (the R&D arm of
the company) and Weather Telematics. As big as the AI market
is (think the “Internet of Things”), the team’s deep
experience was in part responsible for the company’s current
focus.

AI Labs uses proprietary artificial intelligence to build
solutions for the public safety and security markets, a
subsector that is projected to reach more than US$900 billion
by 2027 and is part of a larger overall sector that also
includes energy management, smart buildings, mobility,
technology, infrastructure, and healthcare, which are expected
to total US$1.56 trillion by 2025.

AI Labs is currently building solutions for real-world
problems and has successfully developed a patent-pending fever
detection system (ThermalPass). Since the start of the
coronavirus pandemic, the way the world now operates will be
forever changed. As announced earlier in October, Predictiv
AI, via a joint venture with Commersive Solutions Corp., has
transitioned from the prototype phase into the
commercialization phase. An Ontario Canada-based trucking
company was the first to deploy the system commercially on
October 13, 2020.

The ThermalPass Fever Detection System detects body
temperature using multiple touchless, infrared, thermal
medical grade sensors to identify potential at-risk carriers.

The device is efficient and can process up to 60 people per
minute without any need for people to do anything but walk
normally through the sensor system. It is approved by Health
Canada as a class 1 medical device and is a critical real-time
detector that can help companies everywhere in the fight
against the spread of the coronavirus. The uses for this
product are everywhere that people go in public and the market
is massive.

ThermalPass is arguably the best, most effective and simplest
temperature scanning system available. It is also the least
expensive, when compared to competitors in China and the US
and has a patent pending. Currently made in Canada, it is easy
to assemble, there are stationary and mobile versions
available, and the company has secured leading Canadian and US
suppliers to contract manufacture the units. Also, ThermalPass
has the supply chain in place to rapidly scale production to
meet demand. Notably, the US government has put a ban on
Chinese thermal-camera based systems, limiting competition to
the ThermalPass system particularly in the US.

Temperature scanners will probably become a fact of life – the
ability to provide a better mousetrap such as the ThermalPass

product, means that the world should beat a path to company’s
door, based on ease of use, reliability of the technology and
lower than average price.

The second significant product line comes from the Weather
Telematics subsidiary. The company has a product called “Alert
Fleet”, which uses advanced AI and deep machine learning to
generate hyper-local advanced road weather data using Weather
Telematics patented sensors. This is a critical piece of
technology that could save the trucking industry significant
time (and money) by being to avoid serious weather conditions,
winter and summer.

Alert Fleet can generate real-time road alerts 200-300 meters
ahead, 1 km ahead and 100s of kilometers in advance of
hazardous road conditions and can provide up to 72 hour
advanced proprietary predictive weather data using patented AI
and sensor technology. It can alert to winter conditions
(snow, ice, black ice), hydroplaning/flooding risk, low
visibility (fog) risk as well as wind, hail and lightening
risks. It can be a standalone product, can be integrated into
existing telematics service provider portals and can be
delivered inside the vehicle as well as to a dispatcher via
text messaging, email or mobile app integrations.

The company has a market capitalization of approximately
C$19.5 million and just completed a share consolidation in
August 2020, along with the changing of the company’s name to
Predictiv AI Inc. (previously Internet of Things Inc.). The
company has a small amount of debt ($311,000) mostly in the
form of a demand loan, but in early October 2020 closed a
nonbrokered private placement of $1.5 million primarily to
fund the ThermalPass production planning and manufacturing as
well as providing capital to AI Labs for ongoing R&D. While it
is still early days for investors in this company, there
appears to be a particularly bright future ahead in an ever
changing world.

AI for the next generation of
medical imaging provides “a
Google Maps for surgeons”
“A Google Maps for surgeons” is how Perimeter Medical Imaging
AI Inc. (TSXV: PINK) President and CFO Jeremy
Sobotta described the AI software currently being developed by
the company to complement its FDA-cleared medical imaging
system at a recent investment conference.

Perimeter is a medical technology company working to transform
cancer surgery by creating ultra-high-resolution, real-time,
advanced imaging tools to address unmet medical needs. The
imaging tools have already been developed and are approved in
ophthalmology and cardiology (optical coherence tomography or
OCT). Perimeter is using this imaging technology (OTIS or
Optical Tissue Imaging Console) to assess the tissues
surrounding the known cancerous target area to determine
whether more tissue should be removed during the ongoing
surgery.

The imaging technology has the ability to rapidly image large
and complex surfaces. It is capable of imaging up to a 10×10
centimeter surface area at resolutions ten to 100 times that
of traditional imaging systems (and also has a system that
enables the orientation and imaging of any size, shape and/or
density of specimen). Of note, the company’s device is
commercial, is FDA-cleared and will be launched into the early
adopter market later in 2020/early 2021.

As previously announced, Perimeter Medical Imaging received a
$7.4 million Cancer Prevention and Research Institute of Texas

(CPRIT) grant to further develop the ATLAS AI Project. The
funding granted by CPRIT will support technology development
that is currently underway with the first part being data
collection to further train and test the AI algorithm. Part
two will be undertaken in early 2021 to confirm the safety and
efficacy of the technology/process that aims to decrease the
re-operation rates for breast cancer patients. Future
deployment of the AI technology will be complementary to OTIS,
once it has been FDA-approved.

As described in the September 16, 2020 online presentation,
the company has engaged with world-renowned cancer centers in
Canada, the US and Europe and has attracted an exceptional
scientific advisory board. Members include medical
professionals affiliated with the Harvard Medical School, the
Mayo Clinic Cancer Centre, and the Ontario Cancer Institute in
addition to others, which is an exceptional validation of this
company’s early-stage technology. Management is deeply
experienced in the medical-technology industry, and the board
of directors has a wealth of expertise in clinical experience,
surgical workflows, and medical device commercialization.

The company went public at the end of June 2020 through a
reverse takeover transaction and concurrent financing, and has
access to approximately $30 million of capital, so near-term
development is well-funded as the company looks to sell up to
half a billion dollars of installations into an undersupplied
market.

Perimeter’s technology is addressing an unmet need in a $3.7
billion addressable market segment, according to the World
Health Organization. It should be noted that this technology
is not just restricted to breast cancer surgery, but is
potentially applicable to a wide variety of other cancer and
other treatments as shown below:

Source: Perimeter Medical Imaging AI

Finally, an estimated one in four women require repeat breast
cancer surgery due to cancerous tissue remaining after the
initial surgery. Perimeter’s use of existing technology and a
machine learning/artificial intelligence combination is
designed to significantly lessen this statistic. While it is
too early to declare that this one technology is the “holy
grail”, it does bring us one step closer to the statement that
“cancer can be beaten”.

StageZero Saliva PCR Test, a
potential game changer for
replacing the nasal probe
Nobody likes a COVID-19 nasal swab test that pushes a probe
way up into your nose nearly reaching your brain. StageZero
Life Sciences Ltd. (TSX: SZLS) (‘StageZero’) has released a
COVID-19 saliva PCR test in the USA which is so much more

easier and more comfortable to do. It can even be mailed to
you and done at your home.

In news just released yesterday, StageZero released their new
COVID-19 Saliva PCR test in the USA and Canada. Since May
2020, StageZero has been offering nasopharyngeal swab-based
PCR tests and serology tests for COVID-19. The good news is
that StageZero has now added a saliva test and will shortly
introduce an antigen test and a full viral respiratory panel
to its test offering. The test is FDA approved under the
Emergency Use Authorization (EUA) clearance. All the patient
has to do is simply fill a tube with their own saliva, label
it, and send it to the StageZero lab for testing.

COVID-19 PCR test – Uncomfortable nasal swab versus simple
saliva testing

Source

Chairman and CEO of StageZero, James Howard-Tripp, says:
“Every COVID testing lab, and Government, is striving to make
testing more accessible and easier to do. Saliva as a
specimen, done correctly, is scientifically as accurate as
swabs but easier to collect and allows us to reach patients at
home.”

Back in May when StageZero first introduced the nasal swab

tests I wrote about the massive worldwide demand for COVID-19
testing. I quoted a report by Harvard University stating that
the US needs to be able to test 5 million people per day to
safely begin to reopen their economy by June 2020. That was
when there were only 30,000 new cases per day in the USA.

Fast forward to today and there are now about 45,000 new
COVID-19 cases per day in the US, and about 1 million new
COVID-19 tests performed every day. But really the need for
testing remains much higher.

US daily COVID-19 tests tracker by John Hopkins – About 1
million tests per day

Source

StageZero will continue to offer a selection of COVID-19
testing summarized as:

     Salvia PCR tests to detect the SARS-CoV-2 RNA and then
     sent to the StageZero Virginia lab for results
     processing. Ideal for very early stage detection.
     Antigen testing for immediate results. This works by
     testing if a patient has developed antibodies to

COVID-19. It is best for the rapid screening of
     symptomatic patients.
     A Respiratory Panel PCR-based test for 18 viruses and
     two respiratory bacteria. It will screen for Influenza
     A, Influenza B, RSV and SARS-CoV-2 infection.

StageZero now offers a complete range of COVID-19 tests at a
time when demand for testing is enormous. My view is that
patient’s will be much more willing to undergo a saliva test
than the previous nasal swab testing, as well as the
possibility of completing a test from home. It is also much
more suitable for people in remote areas.

Looking ahead in the very near term, StageZero will commence
an offering with their revolutionary Aristotle® screening test
for 10 cancers from a single sample of blood. You can read
more about that here.

Following the recent share consolidation StageZero will now
“prepare for a possible future listing on NASDAQ or other
senior US stock exchange“. Both of these events should be
strong catalysts to help the stock price potentially move
higher.

StageZero Life Sciences trades with a market cap of just C$41
million. Analyst’s consensus price target is C$4.00, so there
is still plenty of potential upside ahead given the current
stock price of C$0.84.

Disclaimer: Matt Bohlsen is a shareholder of StageZero Life
Sciences Ltd. (TSX: SZLS)

Drolet   Stock    Notes   on
Diagnos: AI driven retina
analysis    tool   for   the
detection of critical health
issues
Mario Drolet, President of MI3 Communications Financières Inc.
(MI3), released his Drolet Stock Notes on Diagnos Inc. (TSXV:
ADK | OTCQB: DGNOF) on October 7, 2020 for exclusive
distribution on InvestorIntel. Highlights include:

     Diagnos has a mission of early detection of critical
     health issues using its Artificial Intelligence (“AI”)
     tool CARA (Computer Assisted Retina Analysis).
     CARA complies with local regulations, is FDA cleared for
     commercialization in the United States of America is
     Health Canada licensed for commercialization in Canada
     and is CE marking compliant in Europe.
     Diagnos signed a contract with Devlyn Grupo, an
     important optical retailer with over nine hundred stores
     in Mexico and Guatemala.
     ADK traded over 21 million shares over the last three
     months between $0.46 & $0.135
     Support: S2; $ 0.28      S1; $ 0.33    Resistance:   R1;
     $0.395    R2; $0.46

About Diagnos

Diagnos is a publicly-traded Canadian corporation with a
mission of early detection of critical health issues through
the use of its Artificial Intelligence (“AI”) tool CARA
(Computer Assisted Retina Analysis). CARA is a tele-
ophthalmology platform that integrates with existing equipment
(hardware and software) and processes at the point of care.
CARA’s Artificial Intelligence image enhancement algorithms
make standard retinal images sharper, clearer and easier to
read. CARA is accessible securely over the internet, and is
compatible with all recognized image formats and brands of
fundus cameras, and is EMR compatible. CARA is a cost-
effective tool for screening large numbers of patients in
real-time. CARA complies with local regulations, is FDA
cleared for commercialization in the United States of America
is Health Canada licensed for commercialization in Canada and
is CE marking compliant in Europe.

PLEASE DO YOUR DUE DILIGENCE

Disclaimer: This Mario Drolet Stock Notes are produced by MI³
Communications Financières is neither an offer to sell, nor

the solicitation of an offer to buy any of the securities
discussed therein. The information contained is prepared by
MI3, emanating from sources deemed to be reliable. MI3
Communications Financières makes no representations or
warranties with respect to the accuracy, correctness or
completeness of such information. MI³ Communications
Financières accepts no liability whatsoever for any loss
arising from the use of the information contained therein.
Please take note that for compliance purposes, all directors,
consultants or employees of MI3 Communications Financières are
prohibited from trading the securities of the company and MI3
Communications Financières is a shareholder and do not intend
to sell any shares during the distribution of this report.

Trump’s test results fuel
global market uncertainty,
increase interest in Vice-
Presidential debate
Rising early AM to the Trump COVID-19 breaking news, the
emails abound with commentary that ranges from the increasing
interest in the Vice-Presidential debate to sincere concerns
surrounding his health. Sr Editor Frederick Kozak text
messaged us with: “There’s so much uncertainty in the global
markets right now and Trump’s positive test will only add to
it. It’s damned inconvenient to have this in the last month of
the campaign. More uncertainty will be the order of the day.”

Henry Weingarten sent me his thoughts early AM with: “Markets
hate uncertainty. Today’s bombshell announcement about Trump’s

COVID-19 positive test is just that. Hence markets are
dropping….keep in mind that this could shake up the
presidential race in an unexpected way by focusing on the Vice
President in 2021.”

Let’s turn our attention to “the other big news from the White
House just two days earlier that an Executive Order has been
issued declaring “a national emergency” to deal with the
threat of a lack of critical minerals supply chain for the
US.” as Sr Editor Matt Bohlsen wrote this morning in his
column titled White House News: Trumps test positive for
COVID-19 and critical materials national emergency declared.

In my opinion, the best written material on the Executive
Order was issued in a news release by Energy Fuels Inc. (NYSE
American: UUUU | TSX: EFR) yesterday titled: Energy Fuels
Applauds President Trump’s Executive Order Declaring State of
Emergency to Address America’s Overreliance on Critical
Minerals from Foreign Adversaries; Includes Uranium, Vanadium
and Rare Earth Elements.

Mark S. Chalmers, President and CEO of Energy Fuels stated:
“President Trump made a strong statement last night (September
30, 2020) on the importance of bringing the production of
critical minerals back to the United States. In 2018, the
Administration deemed 35 minerals critical to U.S. national
security and the economy. For 31 of these 35 minerals, the
U.S. imports more than half of our requirements. And, for 14
of these 35 minerals, the U.S. is effectively 100% dependent
on imports. These minerals are needed for aerospace,
computers, cell phones, electrical generation and
transmission, renewable energy systems and batteries, and
advanced electronics. This is an unacceptable situation for a
superpower like the United States, and we applaud President
Trump for taking bold action to address this critical need.”

Follow-up to this news includes an interview with Jack Lifton
of the Technology Metals Show, we should have this live over

the weekend.

On a final note, we do cover biotech and life sciences and if
your interested in seeing who we are watching in the capital
markets for COVID-19, from our Top 20 companies in the
Disinfection market sector to vaccinations, click here

We will be reviewing at market close today.